Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abdel Salam Attia, Ismail"'
Autor:
Jorge P. Leguizamo, Jean L. Grem, Chris H. Takimoto, Abdel Salam Attia Ismail, Janet Pang, Mary G. Quinn, Michael D. Liang, William L. Dahut
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:333-338
A phase I pharmacologic study was undertaken to determine the maximum tolerated dose (MTD), to characterize the pharmacokinetic profile, and to evaluate all toxicities of the aqueous colloidal dispersion formulation of 9-aminocampothecin (9-AC).9-AC
Autor:
Frank M. Balis, W. Corse, Chris H. Takimoto, David J. Liewehr, Mary Flanagan Quinn, Jean L. Grem, Robert F. Murphy, J M Hamilton, Carmen J. Allegra, Brian P. Monahan, Nancy Harold, Alice P. Chen, Janet Pang, Seth M. Steinberg, R. Lush, Abdel Salam Attia Ismail
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:117-125
Purpose: Clinical toxicity associated with 5-fluorouracil (5-FU) is related to the area under the plasma concentration-time curve (AUC). Recently, short-term infusions of 5-FU given over 30 or 60 min have been substituted for conventional "bolus" 5-F
Autor:
Jean L. Grem, Aaron Ernst, Maurice A. Wright, Vivian Kao, Ilan R. Kirsch, Allison Parr, Liam Grogan, Abdel Salam Attia Ismail, Frank Grollman, Mary G. Quinn
Publikováno v:
Oncology Reports.
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon alpha-2a (IFN-alpha). This phase II study assessed
Autor:
Abdel Salam Attia, Ismail, Mary G, Quinn, Maurice A, Wright, Aaron, Ernst, Vivian, Kao, Liam, Grogan, Allison, Parr, Frank, Grollman, Ilan R, Kirsch, Jean L, Grem
Publikováno v:
Oncology reports. 13(6)
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon alpha-2a (IFN-alpha). This phase II study assessed
Autor:
Jeremy Shapiro, Roger A. Band, Nathan A. Berger, Carmen J. Allegra, Aida Guemei, Mary Flanagan Quinn, Susan G. Arbuck, J. Michael Hamilton, Abdel Salam Attia Ismail, Jean L. Grem, Jeff Cottrell, Alice P. Chen, Sosamma J. Berger, Nancy Harold, Donald Flemming, Haruyo Hirota, Victor Llorens, Geraldine Morrison, Chris H. Takimoto, Hilary Hehman, Brian P. Monahan, David Gosky, John J. Wright
Publikováno v:
Journal of Clinical Oncology. 18:659-659
PURPOSE: We conducted a phase I and pharmacologic study of a weekly 96-hour infusion of irinotecan to determine the maximum-tolerated dose, define the toxicity profile, and characterize the clinical pharmacology of irinotecan and its metabolites. PAT